# OH2 Oncolytic Viral Therapy in Solid Tumors

> **NCT03866525** · PHASE1,PHASE2 · RECRUITING · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Solid Tumor
- Gastrointestinal Cancer

## Interventions

- **BIOLOGICAL:** OH2 injection, with or without irinotecan or HX008

## Key facts

- **NCT ID:** NCT03866525
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-02
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866525, "OH2 Oncolytic Viral Therapy in Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03866525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*